Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome

Jamie O Edgin, Goffredina Spanō, Lynn Nadel

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Considerable progress in our understanding of the cognitive profile of Down syndrome (DS) has occurred in the last decade. Complementing this progress has been a series of landmark studies highlighting promise for pharmacological intervention for cognitive deficits in this population (Fernandez et al., 2007; Salehi et al., 2009). Movement forward has also been demonstrated by the development of behavioral cognitive interventions targeting specific aspects of the cognitive profile (e.g. Fidler et al., Chapter 15 of this book). With pharmacological and behavioral clinical trials coming to fruition in the next few years, there is an immediate need for valid and reliable clinical endpoints in DS. These trials will only be meaningful if they include a battery of measurements that are well suited for this population and sensitive enough to detect change. Our group has been involved in the development of such a battery, the Arizona Cognitive Test Battery (ACTB) (Figure 3.1), which serves as a foundation for assessing characteristics of the phenotype of DS. The history of pharmacological and dietary interventions for the cognitive deficits in humans with DS is largely one of disappointment (Salman, 2002). A number of drugs [e.g. Drugs used in Alzheimer's disease, such as donepezil (Prasher et al., 2002)] or dietary supplements currently on the market have been tested for use in individuals with DS, with little effect on the whole.

Original languageEnglish (US)
Title of host publicationNeurocognitive Rehabilitation of Down Syndrome: The Early Years
PublisherCambridge University Press
Pages36-51
Number of pages16
ISBN (Print)9780511919299, 9781107400436
DOIs
StatePublished - Jan 1 2011

Fingerprint

Down Syndrome
Rehabilitation
Pharmacology
Vulnerable Populations
Dietary Supplements
Pharmaceutical Preparations
Alzheimer Disease
History
Clinical Trials
Phenotype
Population

ASJC Scopus subject areas

  • Psychology(all)

Cite this

Edgin, J. O., Spanō, G., & Nadel, L. (2011). Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome. In Neurocognitive Rehabilitation of Down Syndrome: The Early Years (pp. 36-51). Cambridge University Press. https://doi.org/10.1017/CBO9780511919299.004

Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome. / Edgin, Jamie O; Spanō, Goffredina; Nadel, Lynn.

Neurocognitive Rehabilitation of Down Syndrome: The Early Years. Cambridge University Press, 2011. p. 36-51.

Research output: Chapter in Book/Report/Conference proceedingChapter

Edgin, JO, Spanō, G & Nadel, L 2011, Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome. in Neurocognitive Rehabilitation of Down Syndrome: The Early Years. Cambridge University Press, pp. 36-51. https://doi.org/10.1017/CBO9780511919299.004
Edgin JO, Spanō G, Nadel L. Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome. In Neurocognitive Rehabilitation of Down Syndrome: The Early Years. Cambridge University Press. 2011. p. 36-51 https://doi.org/10.1017/CBO9780511919299.004
Edgin, Jamie O ; Spanō, Goffredina ; Nadel, Lynn. / Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome. Neurocognitive Rehabilitation of Down Syndrome: The Early Years. Cambridge University Press, 2011. pp. 36-51
@inbook{b3d1e1597728420d9fddf8284225a5e5,
title = "Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome",
abstract = "Considerable progress in our understanding of the cognitive profile of Down syndrome (DS) has occurred in the last decade. Complementing this progress has been a series of landmark studies highlighting promise for pharmacological intervention for cognitive deficits in this population (Fernandez et al., 2007; Salehi et al., 2009). Movement forward has also been demonstrated by the development of behavioral cognitive interventions targeting specific aspects of the cognitive profile (e.g. Fidler et al., Chapter 15 of this book). With pharmacological and behavioral clinical trials coming to fruition in the next few years, there is an immediate need for valid and reliable clinical endpoints in DS. These trials will only be meaningful if they include a battery of measurements that are well suited for this population and sensitive enough to detect change. Our group has been involved in the development of such a battery, the Arizona Cognitive Test Battery (ACTB) (Figure 3.1), which serves as a foundation for assessing characteristics of the phenotype of DS. The history of pharmacological and dietary interventions for the cognitive deficits in humans with DS is largely one of disappointment (Salman, 2002). A number of drugs [e.g. Drugs used in Alzheimer's disease, such as donepezil (Prasher et al., 2002)] or dietary supplements currently on the market have been tested for use in individuals with DS, with little effect on the whole.",
author = "Edgin, {Jamie O} and Goffredina Spanō and Lynn Nadel",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9780511919299.004",
language = "English (US)",
isbn = "9780511919299",
pages = "36--51",
booktitle = "Neurocognitive Rehabilitation of Down Syndrome: The Early Years",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Advances in clinical endpoints for neurocognitive rehabilitation in down syndrome

AU - Edgin, Jamie O

AU - Spanō, Goffredina

AU - Nadel, Lynn

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Considerable progress in our understanding of the cognitive profile of Down syndrome (DS) has occurred in the last decade. Complementing this progress has been a series of landmark studies highlighting promise for pharmacological intervention for cognitive deficits in this population (Fernandez et al., 2007; Salehi et al., 2009). Movement forward has also been demonstrated by the development of behavioral cognitive interventions targeting specific aspects of the cognitive profile (e.g. Fidler et al., Chapter 15 of this book). With pharmacological and behavioral clinical trials coming to fruition in the next few years, there is an immediate need for valid and reliable clinical endpoints in DS. These trials will only be meaningful if they include a battery of measurements that are well suited for this population and sensitive enough to detect change. Our group has been involved in the development of such a battery, the Arizona Cognitive Test Battery (ACTB) (Figure 3.1), which serves as a foundation for assessing characteristics of the phenotype of DS. The history of pharmacological and dietary interventions for the cognitive deficits in humans with DS is largely one of disappointment (Salman, 2002). A number of drugs [e.g. Drugs used in Alzheimer's disease, such as donepezil (Prasher et al., 2002)] or dietary supplements currently on the market have been tested for use in individuals with DS, with little effect on the whole.

AB - Considerable progress in our understanding of the cognitive profile of Down syndrome (DS) has occurred in the last decade. Complementing this progress has been a series of landmark studies highlighting promise for pharmacological intervention for cognitive deficits in this population (Fernandez et al., 2007; Salehi et al., 2009). Movement forward has also been demonstrated by the development of behavioral cognitive interventions targeting specific aspects of the cognitive profile (e.g. Fidler et al., Chapter 15 of this book). With pharmacological and behavioral clinical trials coming to fruition in the next few years, there is an immediate need for valid and reliable clinical endpoints in DS. These trials will only be meaningful if they include a battery of measurements that are well suited for this population and sensitive enough to detect change. Our group has been involved in the development of such a battery, the Arizona Cognitive Test Battery (ACTB) (Figure 3.1), which serves as a foundation for assessing characteristics of the phenotype of DS. The history of pharmacological and dietary interventions for the cognitive deficits in humans with DS is largely one of disappointment (Salman, 2002). A number of drugs [e.g. Drugs used in Alzheimer's disease, such as donepezil (Prasher et al., 2002)] or dietary supplements currently on the market have been tested for use in individuals with DS, with little effect on the whole.

UR - http://www.scopus.com/inward/record.url?scp=84926076839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926076839&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511919299.004

DO - 10.1017/CBO9780511919299.004

M3 - Chapter

AN - SCOPUS:84926076839

SN - 9780511919299

SN - 9781107400436

SP - 36

EP - 51

BT - Neurocognitive Rehabilitation of Down Syndrome: The Early Years

PB - Cambridge University Press

ER -